Video

Future Perspectives in Renal Cell Carcinoma (RCC)

Author(s):

Thomas Hutson, DO, PharmD

Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.

Related Videos
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Image of a man wearing a black suit and tie.
Related Content
Dr. Chandler Park helps patients with genitourinary cancer understand the importance of genetic testing: © lucky - stock.adobe.com
February 28th 2025

There is a Growing Need For Genetic Testing and Precision Medicine in GU Cancers

Ryan Scott
Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Maintenance Bavencio with Inlyta treatment interruption is feasible in patients with mRCC: © SciePro - stock.adobe.com.
February 19th 2025

Bavencio Maintenance After Inlyta Interruption Shows Feasibility in mRCC

Jax DiEugenio
Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC: © stock.adobe.com
February 15th 2025

Outcomes May Be Consistent With Fotivda Alone or With Opdivo in Kidney Cancer Subset

Ashley Chan
Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.
Opdivo plus Cometyx resulted in a benefit versus Sutent in the first-line of advanced renal cell carcinoma treatment. © stock.adobe.com
February 15th 2025

Opdivo Plus Cabometyx Safe, Effective in Advanced Renal Cell Carcinoma

Tim Cortese
Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.